Mirador Therapeutics

Redefining Immunology and Inflammation with Precision

Add To Watchlist
General Information
Company Name
Mirador Therapeutics
Founded Year
2024
Location (Offices)
Founders / Decision Makers
Mark McKenna - Founder and CEO
Number of Employees
55
Industries
Health Care, Health and Wellness
Funding Stage
Series A
Social Media

Mirador Therapeutics - Company Profile

Mirador Therapeutics is a cutting-edge precision medicine company founded in 2024, aiming to revolutionize the treatment of immunology and inflammation. With the Mirador360 TM precision development engine, the company harnesses the latest breakthroughs in human genetics and data science to expedite the creation of novel medications tailored for patients with chronic immune-mediated inflammatory and fibrotic diseases. Based in San Diego, CA, the startup has accumulated an impressive $400 million in funding from prominent life sciences investors. Notable contributors to this Series A investment on 21 March 2024 include OrbiMed, Alexandria Venture Investments, Fidelity, RTW Investments, TCG Crossover, Woodline Partners, Venrock Healthcare Capital Partners, Invus Opportunities, Point72 Ventures, and Fairmount Partners. Mirador's relentless pursuit of precision in healthcare has drawn extensive support, positioning it as a key player in the Health Care and Health and Wellness industries.

Taxonomy: precision medicine, immunology, inflammation, Mirador360, human genetics, data science, precision medicines, chronic diseases, immune-mediated inflammatory diseases, fibrotic diseases, life sciences investors, San Diego, venture capital, startup

Funding Rounds & Investors of Mirador Therapeutics (3)

View All
Funding Stage Amount No. Investors Investors Date
Series A $400.00M 10
OrbiMed, investor in Mirador Therapeutics's Series A round Alexandria Venture Investments, investor in Mirador Therapeutics's Series A round Fidelity, investor in Mirador Therapeutics's Series A round RTW Investments, investor in Mirador Therapeutics's Series A round TCG Crossover, investor in Mirador Therapeutics's Series A round Woodline Partners, investor in Mirador Therapeutics's Series A round Venrock Healthcare Capital Partners, investor in Mirador Therapeutics's Series A round
Invus Opportunities, Point72 Ventures +1 		21 Mar 2024
Debt Financing Unknown - 19 Mar 2024
Venture Round $80.00M - 14 Dec 2023

Latest News of Mirador Therapeutics

View All

No recent news or press coverage available for Mirador Therapeutics.

Similar Companies to Mirador Therapeutics

View All
ENDPOINT HEALTH - Similar company to Mirador Therapeutics
ENDPOINT HEALTH Precision immunology therapies
Solu Therapeutics - Similar company to Mirador Therapeutics
Solu Therapeutics Solu Therapeutics is a next-generation therapeutics focused company working to eliminate cells that drive diseases.
Certa Therapeutics - Similar company to Mirador Therapeutics
Certa Therapeutics Developing innovative precision therapies for the treatment of inflammatory and fibrotic diseases
Santa Ana Bio, Inc. - Similar company to Mirador Therapeutics
Santa Ana Bio, Inc. Precision medicines for serious immune mediated diseases.
Autonomous Therapeutics - Similar company to Mirador Therapeutics
Autonomous Therapeutics Precision medicines via a new class of RNA
Circle Decoration Circle Decoration

Want to dive deeper into Mirador Therapeutics? Join now to access exclusive insights and find similar companies like this — powered by AI analytics.

Register Now